(Q35895287)

11 August 2017

Epoch Analysis of On-Treatment Disability Progression Events over Time in the Tysabri Observational Program (TOP) (English)

1 reference

11 August 2017

0 references

0 references

Helmut Butzkueven

2

0 references

Heinz Wiendl

object named as

Heinz Wiendl

1

0 references

Maria Trojano

object named as

Maria Trojano

4

0 references

Ludwig Kappos

3

object named as

Ludwig Kappos

1 reference

11 August 2017

Fabio Pellegrini

5

1 reference

11 August 2017

Dominic Paes

6

1 reference

11 August 2017

Annie Zhang

7

1 reference

11 August 2017

Shibeshih Belachew

8

1 reference

11 August 2017

Tysabri® Observational Program (TOP) Investigators

9

1 reference

11 August 2017

language of work or name

English

0 references

publication date

15 January 2016

1 reference

11 August 2017

1 reference

11 August 2017

11

1 reference

11 August 2017

e0144834

1 reference

11 August 2017

1

1 reference

Creative Commons Attribution 4.0 International

11 August 2017

start time

15 January 2016

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

cites work

The pathologic substrate of magnetic resonance alterations in multiple sclerosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4714845

Downregulation of macrophage inhibitory molecules in multiple sclerosis lesions

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4714845

Readers guide to critical appraisal of cohort studies: 3. Analytical strategies to reduce confounding

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4714845

Reader's guide to critical appraisal of cohort studies: 2. Assessing potential for confounding

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4714845

Reader's guide to critical appraisal of cohort studies: 1. Role and design

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4714845

Efficacy and safety of natalizumab in multiple sclerosis: interim observational programme results.

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4714845

Natalizumab for relapsing remitting multiple sclerosis

24 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4714845

The efficacy of natalizumab in patients with multiple sclerosis according to level of disability: results of an observational study.

24 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4714845

Efficacy of natalizumab in second line therapy of relapsing-remitting multiple sclerosis: results from a multi-center study in German speaking countries.

24 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4714845

The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL.

24 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4714845

Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study

24 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4714845

Natalizumab plus interferon beta-1a for relapsing multiple sclerosis

24 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4714845

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

24 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4714845

Natalizumab: alpha 4-integrin antagonist selective adhesion molecule inhibitors for MS.

24 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4714845

Assessing disability progression with the Multiple Sclerosis Functional Composite

24 September 2018

1 reference

12 December 2020

Sustained improvement in Expanded Disability Status Scale as a new efficacy measure of neurological change in multiple sclerosis: treatment effects with natalizumab in patients with relapsing multiple sclerosis

1 reference

12 December 2020

Natalizumab vs interferon beta 1a in relapsing-remitting multiple sclerosis: a head-to-head retrospective study

1 reference

12 December 2020

Natalizumab reduces relapse clinical severity and improves relapse recovery in MS

1 reference

12 December 2020

10.1371/JOURNAL.PONE.0144834

Identifiers

DOI

1 reference

11 August 2017

0 references

1 reference

11 August 2017

1 reference